ReviewFrontiers in immunology2026
The immune microenvironment of HPV-associated cancers: from viral oncogenesis to immunotherapy response.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papillomavirus (HPV) is a DNA virus with oncogenic potential. Persistent infections with high-risk HPV genotypes can drive malignant transformation in multiple tissues, resulting in distinct HPV-associated cancers. This review provides an analysis of the tumor microenvironment (TME) in head and neck squamous cell carcinoma (HNSCC) and squamous cell carcinoma of uterine cervix (CESC). First, we briefly introduce the key aspects of HPV biology and the mechanisms of carcinogenesis. We focus on the composition and functional states of immune cells within tumor tissues, highlighting how specific immune cells influence disease progression and clinical outcomes. By linking immunological features to patient prognosis, we outline the similarities and differences between the TME of HNSCC and CESC. Additionally, this review summarizes the current standards of care and emerging therapeutic strategies for patients with HPV-associated tumors. Altogether, by providing recent advances in the understanding of the TME of HPV-associated tumors, this review highlights the potential of targeting immune components within the tumor microenvironment for therapeutic benefit.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.